DS-CTN Data and Safety Monitoring Board (DSMB)
LuMind IDSC and the Down Syndrome Clinical Trials Network are pleased to announce the launch of the DS-CTN Data and
November 16, 2022
LuMind IDSC and the Down Syndrome Clinical Trials Network are pleased to announce the launch of the DS-CTN Data and
Eisai, a Japanese pharmaceutical company, and its partner Biogen, a Massachusetts-based biotechnology company, recently announced positive “topline” results from the
Long-COVID in adults with intellectual disability In a recent report, the National Task Group on Intellectual Disabilities and Dementia Practices
September 16, 2022 Research recently published in the journal Science (Manfredi-Lozano et al., Science 377, eabq4515 (2022)) raises the possibility
Date: 7/28/2022
Last week, Richard A. Fisher, Ph.D. joined LuMind IDSC as Chief Scientific Officer. Dr. Fisher’s appointment follows a five-month, international search to fill this leadership role.
“Along with his deep scientific and drug development experience, Rich brings more than 40 years of industry and management knowledge to our organization. I am confident his unique background and skills will elevate and accelerate LuMind IDSC’s research strategy. He will move our mission forward, and we’re lucky to have him on board,” CEO Hampus Hillerstrom said.
Date: 7/28/2022
Last week, Richard A. Fisher, Ph.D. joined LuMind IDSC as Chief Scientific Officer. Dr. Fisher’s appointment follows a five-month, international search to fill this leadership role.
“Along with his deep scientific and drug development experience, Rich brings more than 40 years of industry and management knowledge to our organization. I am confident his unique background and skills will elevate and accelerate LuMind IDSC’s research strategy. He will move our mission forward, and we’re lucky to have him on board,” CEO Hampus Hillerstrom said.
EXAMINING ADULTS WITH NEUROATYPICAL CONDITIONS FOR MCI/DEMENTIA DURING COGNITIVE IMPAIRMENT ASSESSMENTS: REPORT OF THE NEUROATYPICAL CONDITIONS EXPERT CONSULTATIVE PANEL July,
AN EXPLAINER FOR THE DOWN SYNDROME COMMUNITY April 15, 2022 BACKGROUND On April 7, 2022, the federal Centers for
Date: 4/8/2022
Your advocacy is making a difference! The Down Syndrome Coalition, along with our colleagues from the Down Syndrome Diagnosis Network (DSDN), Down Syndrome Medical Interest Group-USA (DSMIG), International Mosaic Down Syndrome Association (IMDSA), and National Task Group on Intellectual Disabilities and Dementia Practices (NTG), and in partnership with our self-advocates and families, succeeded in removing discriminatory language from an important healthcare coverage determination that would have excluded people with Down syndrome from clinical trials for a new class of Alzheimer’s treatments. Read more…
Date: 4/8/2022
Your advocacy is making a difference! The Down Syndrome Coalition, along with our colleagues from the Down Syndrome Diagnosis Network (DSDN), Down Syndrome Medical Interest Group-USA (DSMIG), International Mosaic Down Syndrome Association (IMDSA), and National Task Group on Intellectual Disabilities and Dementia Practices (NTG), and in partnership with our self-advocates and families, succeeded in removing discriminatory language from an important healthcare coverage determination that would have excluded people with Down syndrome from clinical trials for a new class of Alzheimer’s treatments. Read more…